Metformin/Repaglinide (PrandiMet) for Type 2 Diabetes
A new fixed-dose tablet (PrandiMet - Novo Nordisk) combining metformin (Glucophage, and others) and repaglinide (Prandin) has been approved by the FDA for treatment of type 2 diabetes in patients already taking both metformin and repaglinide, or for patients not adequately controlled on either drug alone....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Metformin/Repaglinide (PrandiMet) for Type 2 Diabetes
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1313
Article Code: 1313b
Date: June 1, 2009
Volume: 51
Pages: 41-43
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1313
Article Code: 1313b
Date: June 1, 2009
Volume: 51
Pages: 41-43
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)